MAGNIFICAT project: dual user and harm reduction potential
On 19th January, in Hotel Palace Catania, there was a Kick-Off meeting held by CoEHAR, its Partners: ABF GmbH from Germany, PRATIA MTZ from Poland and supporting Parties such as…
Kick-off meeting of MAGNIFICAT, the new CoEHAR project
This study, strongly advocated by Prof. Riccardo Polosa, aims to investigate the consequences of the combined use of conventional cigarettes and electronic cigarettes on human health.
BREAKTHROUGH STUDY REVEALS VARENICLINE AND COUNSELING EFFECTIVE FOR DUAL USERS IN SMOKING CESSATION
The study found that the antismoking medication varenicline can increase rates of smoking abstinence without causing serious adverse events.
CoEHAR: NO HEALTH RESPIRATORY EFFECTS REPORTED WITH ECIG SUBSTITUTION FOR SMOKING
In their work “Respiratory health effects of e-cigarette substitution for tobacco cigarettes: a systematic review”, researchers analyzed 16 studies from 20 publications: most of the studies showed no difference in respiratory parameters. This indicates that electronic nicotine delivery systems substitution for smoking likely does not result in additional harm to respiratory health.
REPLICA STUDY: CoEHAR research shows minimal to zero cancerogenic effects of e-cigarettes
Replica researchers performed a standard toxicology battery of three assays used for product assessment and regulatory applications.
DiaSmokeFree Working Group Challenges American Diabetes Association Guidelines on E-Cigarette Use
The DiaSmokeFree Working Group send a letter to the American Diabetes Association (ADA) expressing concern and seeking correction of a couple of statements in the ADA guidelines regarding the use…
Lives Saved, Polosa: : “The report offers clear guidance for decision makers”
Today has been released the report “Lives Saved Report - Integrating harm reduction into tobacco control”, indicating that significant lives can be saved through the widespread adoption of THR and…
Polosa at the 26th THR Conference in Durham (USA)
At 11.15 am, October 19, prof. Polosa will host remotely the panel Longer Term Outcomes of Cessation and Harm Reduction with a presentation on "Changes in Health Symptoms - Results and Analysis Methodologies".
GTNF 2023: Polosa at the conference in Seoul, South Korea
“𝑊𝑒 𝑛𝑒𝑒𝑑 𝑡𝑜 𝑐𝑜𝑙𝑙𝑎𝑏𝑜𝑟𝑎𝑡𝑒 𝑡𝑜𝑔𝑒𝑡ℎ𝑒𝑟 𝑠𝑜 𝑡ℎ𝑎𝑡 𝑒𝑣𝑒𝑟𝑦 𝑠𝑖𝑛𝑔𝑙𝑒 𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑏𝑒𝑐𝑜𝑚𝑒𝑠 𝑎𝑛 𝑒𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑜𝑜𝑙. 𝑊𝑒 𝑑𝑜𝑛'𝑡 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑢𝑛𝑖𝑠ℎ 𝑎𝑢𝑡ℎ𝑜𝑟𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑗𝑢𝑛𝑘 𝑝𝑎𝑝𝑒𝑟𝑠, 𝑤𝑒 𝑤𝑎𝑛𝑡 𝑡𝑜 𝑝𝑟𝑜𝑣𝑖𝑑𝑒 𝑡ℎ𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 𝑡𝑜 𝑖𝑚𝑝𝑟𝑜𝑣𝑒”
Bari, Polosa: “Risk reduction to fight atherosclerosis”
“However, it is important to understand a fact when talking about smoking: even today, nicotine is believed to play a major role in the developing of atherosclerosis” explains prof. Polosa “Nicotine does not cause atherosclerosis. In a survey conducted by SERMO on 1000 Italian doctors, it was found that 62 percent of the sample still think that atherosclerosis is caused by nicotine. The fact that 33 percent of the sample is made up of cardiologists is significant".
